2-ethenyl-3,4-dihydro-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester | 335265-99-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-ethenyl-3,4-dihydro-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester
• 英文别名: phenylmethyl 2-ethenyl-4-oxo-3,4-dihydro-1(2H)-pyridinecarboxylate；Benzyl 2-ethenyl-4-oxo-2,3-dihydropyridine-1-carboxylate
• CAS: 335265-99-1
• 化学式: C₁₅H₁₅NO₃
• 分子量: 257.289
• InChiKey: QEDZOKDSZSLZMX-UHFFFAOYSA-N

物化性质

• 沸点：
  392.2±42.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-ethenyl-3,4-dihydro-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester 在 N-碘代丁二酰亚胺 、 羟基甲苯磺酰碘苯 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以67%的产率得到5-iodo-1-((benzyloxy)carbonyl)-2-vinyl-2,3-dihydro-4-pyridone
  参考文献：
  名称：

  N-酰基-2-烷基（芳基）-5-乙烯基-2,3-二氢-4-吡啶酮的狄尔斯-阿尔德反应

  摘要：

  现成的N-酰基-5-乙烯基-2,3-二氢-4-吡啶酮与各种亲二烯体进行Diels-Alder环化反应，得到含有合成有用功能的新型八氢喹啉。用二氢吡啶酮5和顺式二取代的双亲二烯体，以良好至优异的产率获得作为单一非对映异构体的所得环加合物。对应的反应5丙烯酸甲酯，丙烯腈和苯基乙烯基砜的芳族化合物对内加合物表现出适度的偏爱。考察了二氢吡啶酮C-2和C-4取代基对非对面控制程度的影响。通过使用这种方法，以立体控制的方式制备了gephyrotoxin的核心十氢喹啉骨架。在某些亲二烯体上观察到有趣的反应性，导致最初形成的环加合物开环。该串联反应提供了获得独特取代的β-氨基酮，醇和非天然氨基酸的途径。

  DOI：

  10.1021/jo050559n
• 作为产物：
  描述：

  4-甲氧基吡啶 、 乙烯基溴化镁 、 氯甲酸苄酯 以 四氢呋喃 为溶剂， 反应 0.33h， 以86%的产率得到2-ethenyl-3,4-dihydro-4-oxo-1(2H)-pyridinecarboxylic acid phenylmethyl ester
  参考文献：
  名称：

  通过闭环烯烃复分解合成桥连氮杂双环结构。

  摘要：

  已经开发了一种简便合成氮杂双环[mn1]烯烃（m = 3-5; n = 3，2）的新策略，该策略涉及顺式-2,6-二烯基-N的闭环易位（RCM）反应。 -酰基哌啶衍生物。从戊二酰亚胺（11）开始的六步中或从4-甲氧基吡啶（25）开始的三步中可以容易地制备必需的2，6-二烯基哌啶。在确定该方法实用性的一个实例中，制备了官能化的8-氮杂双环[3.2.1]辛烷32，其是合成各种托烷生物碱的潜在中间体。另外，已经开发出构建桥接的四氢-β-咔啉环系统5的新途径，其特征在于烯炔45的闭环易位以在46中构建桥环。到46的这种简明路线还具有潜在的通用性和有用的程序，用于从酯官能团一步制备末端炔烃。46中乙烯基的选择性氧化提供了不饱和醛47，其可以用作合成几种Sarpagine生物碱的有用中间体。

  DOI：

  10.1021/jo0349936

文献信息

• [EN] CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES D'AMINE CYCLIQUES, PROCEDES DE PREPARATION DE CEUX-CI ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLAXO GROUP LTD

  公开号：WO2004099143A1

  公开（公告）日：2004-11-18

  A compound of formula (I) wherein R represents a radical selected from i) ii) iii) iv) where the substituents R1, R2, R3, R4, R4, R7 and the indices m, n and p are as defined in the description; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  式（I）的化合物，其中R代表从i）ii）iii）iv）中选择的基团，其中取代基R1、R2、R3、R4、R5、R6、R7和指数m、n和p如描述中所定义；或其药学上可接受的盐和溶剂；它们的制备方法到含有它们的药物组合物以及它们在治疗由速效肽激酶介导的病症和/或通过选择性抑制血清素再摄取转运蛋白介导的病症中的应用。
• Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them
  申请人：Alvaro Giuseppe

  公开号：US20070073061A1

  公开（公告）日：2007-03-29

  A compound of formula (I) wherein R is a radical selected from in which R 7 is halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; p is an integer from 0 to 3; R 1 is hydrogen, halogen, cyano, C 2-4 alkenyl, C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 is hydrogen or C 1-4 alkyl; R 3 and R 4 independently are hydrogen, C 1-4 alkyl or R 3 together with R 4 is C 3-7 cycloalkyl; R 5 is phenyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, naphthyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, a 9 to 10 membered fused bicyclic heterocyclic group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl or R 5 is a 5 or 6 membered heteroaryl group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl; R 6 is hydrogen or (CH 2 )qR 8 ; R 8 is hydrogen, C 3-7 cycloalkyl, C 1-4 alkoxy, amine, C 1-4 alkylamine, (C 1-4 alkyl) 2 amine, OC(O)NR 9 R 10 or C(O)NR 9 R 10 ; R 9 and R 10 independently are hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m is zero or 1; n is 1 or 2; q is an integer from 1 to 4; r is 1 or 2; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  化合物的结构式为（I），其中R是选择自以下基团的基团，其中R7是卤素、氰基、C1-4烷基、C1-4烷氧基、三氟甲基或三氟甲氧基；p是从0到3的整数；R1是氢、卤素、氰基、C2-4烯基、C1-4烷基（可选择性地被卤素、氰基或C1-4烷氧基取代）；R2是氢或C1-4烷基；R3和R4分别是氢、C1-4烷基或R3与R4结合形成C3-7环烷基；R5是苯基，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；萘基，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；或9到10个成员的融合双环杂环基团，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；R5也可以是5或6个成员的杂芳基团，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；R6是氢或（CH2）qR8；R8是氢、C3-7环烷基、C1-4烷氧基、胺、C1-4烷基胺、（C1-4烷基）2胺、OC（O）NR9R10或C（O）NR9R10；R9和R10分别是氢、C1-4烷基或C3-7环烷基；m为零或1；n为1或2；q是从1到4的整数；r为1或2；或其药学上可接受的盐和溶剂；制备它们的方法，含有它们的药物组合物以及它们在治疗由Tachykinins和/或通过选择性抑制血清素再摄取转运蛋白介导的疾病中的用途。
• Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them
  申请人：Alvaro Giuseppe

  公开号：US20090192194A1

  公开（公告）日：2009-07-30

  A compound of formula (I) wherein R is a radical selected from in which R 7 is halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; p is an integer from 0 to 3; R 1 is hydrogen, halogen, cyano, C 2-4 alkenyl, C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 is hydrogen or C 1-4 alkyl; R 3 and R 4 independently are hydrogen, C 1-4 alkyl or R 3 together with R 4 is C 3-7 cycloalkyl; R 5 is phenyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, naphthyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, a 9 to 10 membered fused bicyclic heterocyclic group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl or R 5 is a 5 or 6 membered heteroaryl group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl; R 6 is hydrogen or (CH 2 )qR 8 ; R 8 is hydrogen, C 3-7 cycloalkyl, C 1-4 alkoxy, amine, C 1-4 alkylamine, (C 1-4 alkyl) 2 amine, OC(O)NR 9 R 10 or C(O)NR 9 R 10 ; R 9 and R 10 independently are hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m is zero or 1; n is 1 or 2; q is an integer from 1 to 4; r is 1 or 2; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  化合物的公式（I），其中R是从以下选择的基团：其中R7是卤素，氰基，C1-4烷基，C1-4烷氧基，三氟甲基或三氟甲氧基；p是从0到3的整数；R1是氢，卤素，氰基，C2-4烯基，C1-4烷基（可以被卤素，氰基或C1-4烷氧基取代）；R2是氢或C1-4烷基；R3和R4独立地是氢，C1-4烷基或R3与R4一起是C3-7环烷基；R5是苯基，它被1到3个独立选择的基团取代，这些基团是三氟甲基，C1-4烷基，氰基，C1-4烷氧基，三氟甲氧基，卤素或（SO）rC1-4烷基，萘基，它被1到3个独立选择的基团取代，这些基团是三氟甲基，C1-4烷基，氰基，C1-4烷氧基，三氟甲氧基，卤素或（SO）rC1-4烷基，或R5是5或6成员的杂芳基，它被1到3个独立选择的基团取代，这些基团是三氟甲基，C1-4烷基，氰基，C1-4烷氧基，三氟甲氧基，卤素或（SO）rC1-4烷基；R6是氢或（CH2）qR8；R8是氢，C3-7环烷基，C1-4烷氧基，胺，C1-4烷基胺，（C1-4烷基）2胺，OC（O）NR9R10或C（O）NR9R10；R9和R10独立地是氢，C1-4烷基或C3-7环烷基；m为零或1；n为1或2；q是从1到4的整数；r为1或2；或其药学上可接受的盐和溶剂；它们的制备过程，包含它们的制药组合物以及它们在治疗通过调节Tachykinins和/或通过选择性抑制血清素再摄取转运蛋白介导的疾病中的应用。
• A ring-closing olefin metathesis approach to bridged azabicyclic structures
  作者：Christopher E Neipp、Stephen F Martin

  DOI：10.1016/s0040-4039(02)00100-4

  日期：2002.3

  A facile and general entry to functionalized bridged bicyclic nitrogen heterocycles has been developed that involves the ring-closing metathesis (RCM) of cis-2,6-dialkenyl-N-acyl piperidines that were readily prepared from glutarimide or 4-methoxypyridine. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Reduction of <i>N</i>-Acyl-2,3-dihydro-4-pyridones to <i>N</i>-Acyl-4-piperidones Using Zinc/Acetic Acid
  作者：Daniel L. Comins、Clinton A. Brooks、Charles L. Ingalls

  DOI：10.1021/jo001609l

  日期：2001.3.1